{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:46:42Z","timestamp":1791953202822,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"DOI":"10.1007\/s40121-026-01458-6","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:24:57Z","timestamp":1791825897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenicity and Safety of Single-Dose MenACYW Conjugate Vaccine in Vietnamese Participants Aged \u2265\u00a012 Months: A Phase III, Open-Label Study"],"prefix":"10.1007","clinical-trial-number":[{"clinical-trial-number":"nct06228586","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Vu Dinh","family":"Thiem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Janicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Syrkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vu Hai","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pham Dinh","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao Trung","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Zocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"2, Supplement","key":"1458_CR1","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","volume":"59","author":"F Martin\u00f3n-Torres","year":"2016","unstructured":"Martin\u00f3n-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59(2, Supplement):S12\u201320.","journal-title":"J Adolesc Health"},{"key":"1458_CR2","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/B978-0-323-79058-1.00039-6","volume-title":"Plotkin's vaccines","author":"LA McNamara","year":"2023","unstructured":"McNamara LA, Pollard AJ, Harrison LH. Chapter 39\u2014meningococcal capsular group A, C, W, and Y conjugate vaccines. In: Orenstein W, Offit P, Edwards KM, Plotkin S, editors. Plotkin\u2019s vaccines. Eighth Edition. Philadelphia: Elsevier; 2023. p. 664- 89.e12.","edition":"Eighth Edition"},{"key":"1458_CR3","unstructured":"World Health Organization (WHO). Meningococcal Meningitis. Available from: https:\/\/www.who.int\/teams\/health-product-policy-and-standards\/standards-and-specifications\/norms-and-standards\/vaccine-standardization\/meningococcal-meningitis."},{"issue":"4","key":"1458_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","volume":"7","author":"KJ Olbrich","year":"2018","unstructured":"Olbrich KJ, M\u00fcller D, Schumacher S, Beck E, Meszaros K, Koerber F. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421\u201338.","journal-title":"Infect Dis Ther"},{"key":"1458_CR5","first-page":"1","volume-title":"Neisseria meningitidis: methods and protocols","author":"S Hollingshead","year":"2019","unstructured":"Hollingshead S, Tang CM. An overview of Neisseria meningitidis. In: Seib KL, Peak IR, editors. Neisseria meningitidis: methods and protocols. New York, NY: Springer New York; 2019. p. 1\u201316."},{"issue":"2, Supplement","key":"1458_CR6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","volume":"59","author":"SI Pelton","year":"2016","unstructured":"Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health. 2016;59(2, Supplement):S3\u201311.","journal-title":"J Adolesc Health"},{"issue":"5","key":"1458_CR7","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.jinf.2020.07.025","volume":"81","author":"AMM Aye","year":"2020","unstructured":"Aye AMM, Bai X, Borrow R, Bory S, Carlos J, Caugant DA, et al. Meningococcal disease surveillance in the Asia-Pacific region (2020): the global meningococcal initiative. J Infect. 2020;81(5):698\u2013711.","journal-title":"J Infect"},{"issue":"1","key":"1458_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3947\/ic.2016.48.1.51","volume":"48","author":"JY Heo","year":"2016","unstructured":"Heo JY. Meningococcal disease in Korea: an epidemiologic study of the underestimated infectious disease. Infect Chemother. 2016;48(1):51\u20133.","journal-title":"Infect Chemother"},{"issue":"2","key":"1458_CR9","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.vaccine.2022.10.083","volume":"41","author":"H Takahashi","year":"2003","unstructured":"Takahashi H, Morita M, Kamiya H, Fukusumi M, Sunagawa M, Nakamura-Miwa H, et al. Genomic characterization of Japanese meningococcal strains isolated over a 17-year period between 2003 and 2020 in Japan. Vaccine. 2003;41(2):416\u201326.","journal-title":"Vaccine"},{"issue":"1","key":"1458_CR10","doi-asserted-by":"publisher","first-page":"2172922","DOI":"10.1080\/21645515.2023.2172922","volume":"19","author":"PN The Nguyen","year":"2023","unstructured":"The Nguyen PN, Hung NT, Mathur G, Pinto TJP, Minh NHL. Review of the epidemiology, diagnosis and management of invasive meningococcal disease in Vietnam. Hum Vaccin Immunother. 2023;19(1):2172922.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"1458_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2071077","volume":"18","author":"J Xu","year":"2010","unstructured":"Xu J, Chen Y, Yue M, Yu J, Han F, Xu L, et al. Prevalence of Neisseria meningitidis serogroups in invasive meningococcal disease in China, 2010\u20132020: a systematic review and meta-analysis. Hum Vaccin Immunother. 2010;18(5):2071077.","journal-title":"Hum Vaccin Immunother"},{"key":"1458_CR12","doi-asserted-by":"publisher","first-page":"5261","DOI":"10.2147\/IDR.S339110","volume":"14","author":"CP Van","year":"2021","unstructured":"Van CP, Nguyen TT, Bui ST, Nguyen TV, Tran HTT, Pham DT, et al. Invasive meningococcal disease remains a health threat in Vietnam people\u2019s army. Infect Drug Resist. 2021;14:5261\u20139.","journal-title":"Infect Drug Resist"},{"key":"1458_CR13","unstructured":"Vietnam Medical Association. Four recommendations to prevent meningococcal disease [in Vietnamese]. Available from: http:\/\/tonghoiyhoc.vn\/4-khuyen-cao-phong-chong-benh-viem-mang-nao-do-mo-cau.htm."},{"issue":"6","key":"1458_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2110759","volume":"18","author":"U Thisyakorn","year":"2022","unstructured":"Thisyakorn U, Carlos J, Chotpitayasunondh T, Dien TM, Gonzales MLAM, Huong NTL, et al. Invasive meningococcal disease in Malaysia, Philippines, Thailand, and Vietnam: an Asia-Pacific expert group perspective on current epidemiology and vaccination policies. Hum Vaccin Immunother. 2022;18(6):2110759.","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"1458_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40121-023-00905-y","volume":"13","author":"PNT Nguyen","year":"2024","unstructured":"Nguyen PNT, Thai PQ, Dien TM, Hai DT, Dai VTT, Luan NH, et al. 4CMenB vaccination to prevent meningococcal B disease in Vietnam: expert review and opinion. Infect Dis Ther. 2024;13(3):423\u201337.","journal-title":"Infect Dis Ther"},{"issue":"11","key":"1458_CR16","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1080\/21645515.2017.1356961","volume":"13","author":"Y Masforrol","year":"2017","unstructured":"Masforrol Y, Gil J, Garc\u00eda D, Noda J, Ramos Y, Betancourt L, et al. A deeper mining on the protein composition of VA-MENGOC-BC\u00ae: an OMV-based vaccine against N. meningitidis serogroup B and C. Hum Vaccin Immunother. 2017;13(11):2548\u201360.","journal-title":"Hum Vaccin Immunother"},{"key":"1458_CR17","unstructured":"U.S. Food and Drug Administration. Approval Letter for MenQuadfi (May 23, 2025). Available from: https:\/\/www.fda.gov\/media\/186697\/download."},{"issue":"1","key":"1458_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2588874","volume":"21","author":"JD Campbell","year":"2025","unstructured":"Campbell JD, Gupta S, Dhingra MS, Zambrano B, Gan L, B\u2019Chir S, et al. A phase 3 study to assess the safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in healthy infants in the USA and Puerto Rico. Hum Vaccin Immunother. 2025;21(1):2588874.","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"1458_CR19","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.vaccine.2022.01.050","volume":"40","author":"MJ Cornish","year":"2022","unstructured":"Cornish MJ, Hedrick JA, Gabrielsen AA, Johnson AD, Miriam Pina L, Rehm C, et al. Safety and immunogenicity of an investigational quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in infants and toddlers: a phase II study. Vaccine. 2022;40(10):1421\u201338.","journal-title":"Vaccine"},{"issue":"8","key":"1458_CR20","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s40121-025-01190-7","volume":"14","author":"F Martinon-Torres","year":"2025","unstructured":"Martinon-Torres F, Virta MM, Koski S, de la Cueva IS, Szymanski HT, Bosis S, et al. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered with routine pediatric vaccines: a European randomized controlled trial. Infect Dis Ther. 2025;14(8):1843\u201365.","journal-title":"Infect Dis Ther"},{"issue":"28","key":"1458_CR21","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1016\/j.vaccine.2020.04.067","volume":"38","author":"A Esteves-Jaramillo","year":"2020","unstructured":"Esteves-Jaramillo A, Koehler T, Jeanfreau R, Neveu D, Jordanov E, Singh Dhingra M. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in \u226556-year-olds: a phase III randomized study. Vaccine. 2020;38(28):4405\u201311.","journal-title":"Vaccine"},{"issue":"1","key":"1458_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2160600","volume":"19","author":"CA Robertson","year":"2023","unstructured":"Robertson CA, Jacqmein J, Selmani A, Galarza K, Oster P. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged \u226559 years: a phase III randomized study. Hum Vaccin Immunother. 2023;19(1):2160600.","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"1458_CR23","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1128\/cdli.4.2.156-167.1997","volume":"4","author":"SE Maslanka","year":"1997","unstructured":"Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The multilaboratory study group. Clin Diag Lab Immunol. 1997;4(2):156\u201367.","journal-title":"Clin Diag Lab Immunol"},{"issue":"8","key":"1458_CR24","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1128\/CVI.05028-11","volume":"18","author":"A Mak Puiying","year":"2011","unstructured":"Mak Puiying A, Santos George F, Masterman K-A, Janes J, Wacknov B, Vienken K, et al. Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis. Clin Vaccine Immunol. 2011;18(8):1252\u201360.","journal-title":"Clin Vaccine Immunol"},{"issue":"10","key":"1458_CR25","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1097\/INF.0000000000002832","volume":"39","author":"CI Baccarini","year":"2020","unstructured":"Baccarini CI, Simon MW, Brandon D, Christensen S, Jordanov E, Dhingra MS. Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine in healthy meningococcal-Na\u00efve children 2\u20139 years of age: a phase III. Randomized Study Pediatr Infect Dis J. 2020;39(10):955\u201360.","journal-title":"Randomized Study Pediatr Infect Dis J"},{"issue":"19","key":"1458_CR26","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1016\/j.vaccine.2020.03.017","volume":"38","author":"L-J Chang","year":"2020","unstructured":"Chang L-J, Hedrick J, Christensen S, Pan J, Jordanov E, Dhingra MS. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine. 2020;38(19):3560\u20139.","journal-title":"Vaccine"},{"issue":"33","key":"1458_CR27","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1016\/j.vaccine.2020.06.013","volume":"38","author":"MS Dhingra","year":"2020","unstructured":"Dhingra MS, Peterson J, Hedrick J, Pan J, Neveu D, Jordanov E. Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: a phase III randomized study. Vaccine. 2020;38(33):5194\u2013201.","journal-title":"Vaccine"},{"key":"1458_CR28","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268821000698","volume":"149","author":"MS Dhingra","year":"2021","unstructured":"Dhingra MS, Namazova-Baranova L, Arredondo-Garcia JL, Kim KH, Limkittikul K, Jantarabenjakul W, et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study. Epidemiol Infect. 2021;149:e90.","journal-title":"Epidemiol Infect"},{"issue":"5","key":"1458_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2052657","volume":"18","author":"M Knuf","year":"2022","unstructured":"Knuf M, R\u00e4met M, Breinholt St\u00e6rke N, Bertrand-Gerentes I, Thollot Y, B\u2019Chir S, et al. Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-na\u00efve toddlers: a randomised, controlled trial. Hum Vaccin Immunother. 2022;18(5):2052657.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"1458_CR30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/14760584.2023.2211162","volume":"22","author":"S Ricci","year":"2023","unstructured":"Ricci S, Azzari C, Amodio E, Castiglia P. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): a review of the evidence and expert opinion. Expert Rev Vaccines. 2023;22(1):447\u201356.","journal-title":"Expert Rev Vaccines"},{"key":"1458_CR31","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268821000261","volume":"149","author":"D van der Vliet","year":"2021","unstructured":"van der Vliet D, Vesikari T, Sandner B, Martin\u00f3n-Torres F, Muzsay G, Forsten A, et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-na\u00efve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study. Epidemiol Infect. 2021;149:e50.","journal-title":"Epidemiol Infect"},{"issue":"6","key":"1458_CR32","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1080\/21645515.2020.1733869","volume":"16","author":"T Vesikari","year":"2020","unstructured":"Vesikari T, Borrow R, Forsten A, Findlow H, Dhingra MS, Jordanov E. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study. Hum Vaccin Immunother. 2020;16(6):1306\u201312.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"1458_CR33","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1080\/21645515.2020.1733867","volume":"16","author":"G \u00c1\u00f1ez","year":"2020","unstructured":"\u00c1\u00f1ez G, Hedrick J, Simon MW, Christensen S, Jeanfreau R, Yau E, et al. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study. Hum Vaccin Immunother. 2020;16(6):1292\u20138.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"1458_CR34","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/21645515.2020.1733868","volume":"16","author":"J Kirstein","year":"2020","unstructured":"Kirstein J, Pina M, Pan J, Jordanov E, Dhingra MS. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study. Hum Vaccin Immunother. 2020;16(6):1299\u2013305.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"1458_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2021.1902701","volume":"18","author":"FM Piazza","year":"2022","unstructured":"Piazza FM, Virta M, Paassilta M, Ukkonen B, Ahonen A, Esteves-Jaramillo A, et al. Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: a phase III, open-label, multi-center study. Hum Vaccin Immunother. 2022;18(1):1\u201310.","journal-title":"Hum Vaccin Immunother"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01458-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01458-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01458-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:07:25Z","timestamp":1791950845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01458-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":35,"alternative-id":["1458"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01458-6","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"20 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following financial interests\/personal relationships, which may be considered as potential competing interests: Vu Dinh Thiem, Vu Hai Ha, Pham Dinh Long and Dao Trung Nguyen report no conflicts of interest. Stephane Janicot is a contractor for Sanofi. Olga Syrkina and C\u00e9line Zocchetti are Sanofi employees and may hold shares and\/or stock options in the company. National Institute of Hygiene and Epidemiology received funding to conduct the administrative and field work.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the protocol and consensus ethical principles derived from international guidelines, including the Declaration of Helsinki and the International Council for Harmonisation guidelines for Good Clinical Practice, including all applicable regulations and directives. The study protocol, informed consent form, investigator\u2019s brochure, and other relevant documents were reviewed and approved by the Independent Ethics Committee and\/or Investigational Review Board for each study site before the study was initiated. The study was registered on ClinicalTrials.gov (NCT06228586).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}